Eledon Pharmaceuticals (2TK) Stock Overview
Operates as a clinical stage biotechnology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
+ 1 more risk
2TK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Eledon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.38 |
| 52 Week High | US$4.66 |
| 52 Week Low | US$1.17 |
| Beta | 0.80 |
| 1 Month Change | 3.76% |
| 3 Month Change | -42.02% |
| 1 Year Change | -66.18% |
| 3 Year Change | -46.51% |
| 5 Year Change | -88.47% |
| Change since IPO | -98.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2TK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.2% | 3.5% | 1.0% |
| 1Y | -66.2% | -31.0% | 15.1% |
Return vs Industry: 2TK underperformed the German Biotechs industry which returned -30.8% over the past year.
Return vs Market: 2TK underperformed the German Market which returned 15% over the past year.
Price Volatility
| 2TK volatility | |
|---|---|
| 2TK Average Weekly Movement | 21.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2TK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2TK's weekly volatility has increased from 14% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 31 | DA Gros | eledon.com |
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
Eledon Pharmaceuticals, Inc. Fundamentals Summary
| 2TK fundamental statistics | |
|---|---|
| Market cap | €103.91m |
| Earnings (TTM) | -€70.56m |
| Revenue (TTM) | n/a |
Is 2TK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2TK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$82.67m |
| Earnings | -US$82.67m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2TK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 11:19 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eledon Pharmaceuticals, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Alethia Young | Cantor Fitzgerald & Co. |